Successfully reported this slideshow.
Your SlideShare is downloading. ×

Сулаєва О.М. - Молекулярна діагностика в менеджменті пацієнтів з рмз

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Loading in …3
×

Check these out next

1 of 19 Ad

Сулаєва О.М. - Молекулярна діагностика в менеджменті пацієнтів з рмз

Навчальний курс: «Молекулярна онкологія, патологія та генетика»

Медична лабораторія CSD спільно з Center for research and education of translational biology and medicine (www.tbm.center ) пропонує безкоштовний курс навчальних лекцій для усіх бажаючих.

Навчальний курс: «Молекулярна онкологія, патологія та генетика»

Медична лабораторія CSD спільно з Center for research and education of translational biology and medicine (www.tbm.center ) пропонує безкоштовний курс навчальних лекцій для усіх бажаючих.

Advertisement
Advertisement

More Related Content

Slideshows for you (20)

More from AlinaPokhilko (20)

Advertisement

Сулаєва О.М. - Молекулярна діагностика в менеджменті пацієнтів з рмз

  1. 1. MOLECULAR DIAGNOSTICS IN BREAST CANCER MANAGEMENT Oksana Sulaieva
  2. 2. CONVENTIONAL DECISION-MAKING APPROACH IN BREAST CANCER Clinical diagnosis Prognosis Tailored treatment
  3. 3. Yuan J et al. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 2018 Oct 8;34(4):549-560.e9. doi: 10.1016/j.ccell.2018.08.019. WHY DO WE NEED MOLECULAR TESTING in BREAST CANCER?
  4. 4. Reason # 1
  5. 5. Major cancer susceptibility loci identified in breast cancer. WHY DO WE NEED MOLECULAR TESTING in BREAST CANCER? Santarpia L. et al. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist. 2016 Sep;21(9):1063-78. doi: 10.1634/theoncologist.2015-0369.
  6. 6. What genes should be tested? CLINICAL IMPLICATIONS • risk assessment • prognosis • targeted treatment NGS TESTING SHOULD BE PREFERRED FOR assessing BRCA1/2 and other HRR-genes
  7. 7. Reason # 2
  8. 8. MOLECULAR TOOLS FOR BREAST CANCER (LUMINAL SUBTYPES, EARLY STAGES) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 7.2021 – August 23, 2021
  9. 9. 10 Oncotype DX Breast
  10. 10. Reason # 3
  11. 11. WHY DO WE NEED MOLECULAR TESTING in BREAST CANCER? List of recurrent drivers in breast cancer Condorelli R et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.
  12. 12. LIST OF GENOMIC ALTERATIONS OF LOE I/II Condorelli R et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.
  13. 13. Tailoring treatment for the best patients’ benefits NGS-panels (Illumina platform) Complex genomic profiling – Foundation One Dx All the types of genetic alterations Complex genomic signatures SHIFTING HEALTH CARE PARADIGM TOWARDS PRECISE MEDICINE
  14. 14. Reason # 4
  15. 15. Tools for molecular residual disease detection and optimizing patients' management
  16. 16. MOLECULAR TESTING APPLICATIONS: • Hereditary cancer diagnostics and family risks assessment • Identifying patients with high risk of recurrence and making a decision on the best treatment options (Luminal Types) • Evaluating predictive markers for tailoring treatment for the best patients benefits • Non-invasive cancer monitoring and molecular residual disease detection • Comprehensive genomic profiling supports clinicians in decision making and improves patients` outcomes and care NGS-panels for solid tumors NGS-panel for BRCA1/2 testing 30-genes panel for hereditary cancer CONCLUSIONS
  17. 17. THANK YOU FOR ATTENTION!

Editor's Notes

  • Currently decision making when dealing
    Pathocolgic complete response
  • Having such an efficient tool do ewe really need moleculartesting for patietns with breast cancer

×